Marijuana stocks weekly investor roundup: Analysis of the week's most important events in the cannabis industry (March 30)
PotNetwork is pleased to bring you our Marijuana Stock Weekend from our partner publication Grizzle. Grizzle journalist and Head of Research Scott Willis covers the marijuana stock market in-depth, with over 12 years of institutional investment management experience in analyzing both debt and equity securities. He has held senior investment research roles at Credit Suisse and TD Asset Management. He’s also a Chartered Financial Analyst and has been featured on BNN Bloomberg and CBC. For more of Scott’s writing check out Grizzle - the language of new money.
Bottom Line: The SAFE act would open up the banking system to cannabis companies and would be a big deal. It passed the House financial services committee and now will have to make it through a vote from all members of the house before going to the Senate. It is still a long shot to pass in the Senate which is controlled by Republicans and run by Mitch McConnell who is against cannabis legalization.
Bottom Line: Overall what the earnings release makes clear is Cronos will need to do a big transformative deal with their pile of cash to support the current stock price. We think Cronos is a “show me” story for the rest of 2019.
Bottom Line: The number of illegal dispensaries in Toronto declined from 36 to 12 after countrywide legalization, but is back on the rise hitting 29 in March. The black market is still standing in the way of the legal market becoming a runaway success.
Bottom Line: Many of the retail outlets in Ontario look like they will fail to open by April 1. Only 5 out of 25 have their authorization from the province. Even if the delays are caused by the government it looks like these operators are still on the hook for C$12,000-C$24,000 in penalties.
Bottom Line: Walgreens is following in the footsteps of CVS. CBD topicals will now be in 1,700 Walgreens stores and at least 600 CVS locations. This is bullish news for CBD brands who are able to win shelf space. So far Harvest (CSE:HARV) is ahead of the group with its deal to supply CVS.
Bottom Line: Industry forecasts think legal dispensaries in Ontario will pull in at least C$1.25 million a month which would be $15 million a year. For perspective, the 12 dispensaries in Massachusetts are currently pulling in $20 million a year in sales each.
Bottom Line: The last-minute collapse of the New Jersey legalization bill along with the failure of New York to bring legalization to a vote in 2019 demonstrates that it won't always be smooth sailing for cannabis reform. Legalization delays will benefit medical license holders such as Ianthus, Curaleaf, Acreage, MedMen, Harvest and Green Thumb.
Bottom Line: It will be important to see which exchange the ETF trades on. If it trades on a Canadian exchange it will be incrementally positive. The holy grail is an ETF that allows U.S. investors to invest in U.S. multi-state operators. This would provide a huge demand boost for these stocks.
Weekly marijuana stock performance
An important shift has begun in marijuana stock performance. Investors are shifting money out of Canadian stocks and into CSE traded U.S. operators. U.S. operators again outperformed the Canadian large caps up 2 percent compared to a 5 percent decline for the large Canadian growers. The overall marijuana index fell 2 percent this week, underperforming the S&P and the TSX by 3 percent and 2 percent respectively.
So far this year the four largest Canadian LPs have outperformed both the cannabis index as a whole and the U.S. Multi-State Operators but the gap is shrinking. MSO's are up 48 percent while the 4 largest Canadian growers are up 68 percent year to date. Investors should begin rotating into U.S. MSO to take advantage of a more positive news flow and regulatory change than what is happening in Canada.
(Source: New Cannabis Ventures)
Stocks are up big in the first quarter after a terrible end to 2018. We are growing more cautious on the industry over the next few months and think investors who are sitting on unrealized gains may want to move partially into cash and wait for a better entry point.
Distribution bottlenecks and a government monopoly do not bode well for licensed producers' ability to meet or exceed lofty earnings and revenue estimates over the next 9 months, however, so far the market has been happy with any revenue growth even if profitability is nowhere in sight.
Longer term, with the Canadian market legalized, we expect retail and wholesale price compression from a legal oversupply by the second half of 2019. Falling cannabis prices will pressure producer stocks later in 2019. After a shakeout, the remaining stocks will be better positioned as long-term buying opportunities.
- Green Growth Racing to 100 CBD Store Locations
- The politics of marijuana in the U.S. explored
- Curaleaf partners with veterans group to reach potential new veteran patients
- Cresco Labs at final stage of approval to enter Michigan marijuana market
- Bill to Protect Federal Employees who use marijuana introduced in the House
- Tilray subsidiary, Natura Naturals, granted expanded Health Canada License
- After a long delay, Hamilton City Council approves TGOD growing facility
- Canopy Growth launches new cannabis brand with Seth Rogan called Houseplant
- TGOD begins selling cannabis to the public
More on PotNetwork
- The week in Latin American cannabis: Blueberries signs with Argentinian firm, Mexico seeks opinions, and Colombian cannabis a boon for many
- CRONOS Group: The shares react to Q4 shortfall
- Curaleaf Holdings: Why their star continues to shine
- Trulieve versus Liberty Health Sciences